Article Information
History
- May 16, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Oleksii Nikolaienko1,2,
- Hans P. Eikesdal1,2,
- Bjørnar Gilje3,
- Steinar Lundgren4,5,
- Egil S. Blix6,
- Helge Espelid7,
- Jürgen Geisler8,9,
- Stephanie Geisler8,
- Emiel A.M. Janssen10,11,
- Synnøve Yndestad1,2,
- Laura Minsaas1,2,
- Beryl Leirvaag1,2,
- Reidun Lillestøl1,2,
- Stian Knappskog1,2 and
- Per E. Lønning1,2,*
- 1K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen; Bergen, Norway
- 2Department of Oncology, Haukeland University Hospital; Bergen, Norway
- 3Department of Hematology and Oncology, Stavanger University Hospital; Stavanger, Norway
- 4Cancer Clinic, St. Olavs Hospital, Trondheim University Hospital; Trondheim, Norway
- 5Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology; Trondheim, Norway
- 6Department of Oncology, University Hospital of North Norway; Tromsø, Norway
- 7Department of Surgery, Haugesund Hospital; Haugesund, Norway.
- 8Department of Oncology, Akershus University Hospital; Lørenskog, Norway.
- 9Institute of Clinical Medicine, University of Oslo, Norway
- 10Department of Pathology, Stavanger University Hospital; Stavanger, Norway
- 11Department of Chemistry, Bioscience and Environmental Engineering; Stavanger University, Stavanger, Norway
- ↵*Corresponding author: Professor Per E. Lønning, Department of Oncology, Haukeland University Hospital, Jonas Lies vei 65, N5021, Bergen, Norway, Tlf: +47 55 97 20 27, E-mail: per.lonning{at}helse-bergen.no